Proton pump inhibitor

The dual role in gastric cancer

Research output: Contribution to journalArticle

Abstract

Proton pump inhibitors (PPIs) are one of the most frequently used medications for upper gastrointestinal diseases. However, a number of physicians have raised concern about the serious side effects of long-term use of PPIs, including the development of gastric cancer. Recent epidemiological studies have reported a significant association between long-term PPI intake and the risk of gastric cancer, even after successful Helicobacter pylori eradication. However, the effects of PPIs on the development of pre-malignant conditions such as atrophic gastritis or intestinal metaplasia are not fully known, suggesting the need for comprehensive and confirmative studies are needed in the future. Meanwhile, several experimental studies have demonstrated the effects of PPIs in reducing chemoresistance in gastric cancer cells by modulating the acidic microenvironment, cancer stemness and signal transducer and activator of transcription 3 (STAT3) signaling pathway. The inhibitory effects of PPIs on STAT3 activity may overcome drug resistance and enhance the efficacy of conventional or targeted chemotherapeutic agents. Taken together, PPIs may "play dual role" in gastric carcinogenesis and treatment of gastric cancer.

Original languageEnglish
Pages (from-to)2058-2070
Number of pages13
JournalWorld Journal of Gastroenterology
Volume25
Issue number17
DOIs
Publication statusPublished - 2019 Jan 1

Fingerprint

Proton Pump Inhibitors
Stomach Neoplasms
STAT3 Transcription Factor
Atrophic Gastritis
Tumor Microenvironment
Gastrointestinal Diseases
Metaplasia
Drug Resistance
Helicobacter pylori
Epidemiologic Studies
Stomach
Carcinogenesis
Physicians

Keywords

  • Astric cancer
  • Drug resistance
  • Proton pump inhibitor
  • Signal transducer and activator of transcription 3

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Proton pump inhibitor : The dual role in gastric cancer. / Joo, Moon Kyung; Park, Jong Jae; Chun, Hoon-Jai.

In: World Journal of Gastroenterology, Vol. 25, No. 17, 01.01.2019, p. 2058-2070.

Research output: Contribution to journalArticle

@article{f85fd80d3c4e47adbf8455035881f70b,
title = "Proton pump inhibitor: The dual role in gastric cancer",
abstract = "Proton pump inhibitors (PPIs) are one of the most frequently used medications for upper gastrointestinal diseases. However, a number of physicians have raised concern about the serious side effects of long-term use of PPIs, including the development of gastric cancer. Recent epidemiological studies have reported a significant association between long-term PPI intake and the risk of gastric cancer, even after successful Helicobacter pylori eradication. However, the effects of PPIs on the development of pre-malignant conditions such as atrophic gastritis or intestinal metaplasia are not fully known, suggesting the need for comprehensive and confirmative studies are needed in the future. Meanwhile, several experimental studies have demonstrated the effects of PPIs in reducing chemoresistance in gastric cancer cells by modulating the acidic microenvironment, cancer stemness and signal transducer and activator of transcription 3 (STAT3) signaling pathway. The inhibitory effects of PPIs on STAT3 activity may overcome drug resistance and enhance the efficacy of conventional or targeted chemotherapeutic agents. Taken together, PPIs may {"}play dual role{"} in gastric carcinogenesis and treatment of gastric cancer.",
keywords = "Astric cancer, Drug resistance, Proton pump inhibitor, Signal transducer and activator of transcription 3",
author = "Joo, {Moon Kyung} and Park, {Jong Jae} and Hoon-Jai Chun",
year = "2019",
month = "1",
day = "1",
doi = "10.3748/wjg.v25.i17.2058",
language = "English",
volume = "25",
pages = "2058--2070",
journal = "World Journal of Gastroenterology",
issn = "1007-9327",
publisher = "WJG Press",
number = "17",

}

TY - JOUR

T1 - Proton pump inhibitor

T2 - The dual role in gastric cancer

AU - Joo, Moon Kyung

AU - Park, Jong Jae

AU - Chun, Hoon-Jai

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Proton pump inhibitors (PPIs) are one of the most frequently used medications for upper gastrointestinal diseases. However, a number of physicians have raised concern about the serious side effects of long-term use of PPIs, including the development of gastric cancer. Recent epidemiological studies have reported a significant association between long-term PPI intake and the risk of gastric cancer, even after successful Helicobacter pylori eradication. However, the effects of PPIs on the development of pre-malignant conditions such as atrophic gastritis or intestinal metaplasia are not fully known, suggesting the need for comprehensive and confirmative studies are needed in the future. Meanwhile, several experimental studies have demonstrated the effects of PPIs in reducing chemoresistance in gastric cancer cells by modulating the acidic microenvironment, cancer stemness and signal transducer and activator of transcription 3 (STAT3) signaling pathway. The inhibitory effects of PPIs on STAT3 activity may overcome drug resistance and enhance the efficacy of conventional or targeted chemotherapeutic agents. Taken together, PPIs may "play dual role" in gastric carcinogenesis and treatment of gastric cancer.

AB - Proton pump inhibitors (PPIs) are one of the most frequently used medications for upper gastrointestinal diseases. However, a number of physicians have raised concern about the serious side effects of long-term use of PPIs, including the development of gastric cancer. Recent epidemiological studies have reported a significant association between long-term PPI intake and the risk of gastric cancer, even after successful Helicobacter pylori eradication. However, the effects of PPIs on the development of pre-malignant conditions such as atrophic gastritis or intestinal metaplasia are not fully known, suggesting the need for comprehensive and confirmative studies are needed in the future. Meanwhile, several experimental studies have demonstrated the effects of PPIs in reducing chemoresistance in gastric cancer cells by modulating the acidic microenvironment, cancer stemness and signal transducer and activator of transcription 3 (STAT3) signaling pathway. The inhibitory effects of PPIs on STAT3 activity may overcome drug resistance and enhance the efficacy of conventional or targeted chemotherapeutic agents. Taken together, PPIs may "play dual role" in gastric carcinogenesis and treatment of gastric cancer.

KW - Astric cancer

KW - Drug resistance

KW - Proton pump inhibitor

KW - Signal transducer and activator of transcription 3

UR - http://www.scopus.com/inward/record.url?scp=85065887173&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065887173&partnerID=8YFLogxK

U2 - 10.3748/wjg.v25.i17.2058

DO - 10.3748/wjg.v25.i17.2058

M3 - Article

VL - 25

SP - 2058

EP - 2070

JO - World Journal of Gastroenterology

JF - World Journal of Gastroenterology

SN - 1007-9327

IS - 17

ER -